Efficacy and Safety of Hydroxychloroquine for the Treatment of COVID-19: An empirical study

The new coronavirus disease epidemic of 2019 (COVID-19) has spread worldwide. A quick solution to meet the urgent demand for effective treatment may be drug repurposing. To treat COVID-19, evaluated the clinical effectiveness of hydroxychloroquine and chloroquine. The individuals that received a modest COVID-19 score were randomized to obtain the control therapy or hydroxychloroquine 800 milligrams once daily on Day 7 and 250 milligrams for nine days, except the evaluated the clinical effectiveness of hydrochloride and chlorin equine. Compared to the control group (CtrlGrp) (Group 3), adverse reactions were observed more frequently in those taking chloroquine (Group 1) and hydroxychloroquine (Group 2). The time to clinical recovery (TTCR) was shortened in the Group 1 relation to the CtrlGrp. In the Group 2, there was a tendency toward lower TTCR. Chloroquine and Group 2 reached viral RNA negative substantially faster than the CtrlGrp. The typical instances to become RNA negative in the groups treated with chloroquine, hydroxychloroquine, and controls comprised two days, two weeks, and seven days, correspondingly. Both the length of hospitalization and the results of the lung computed tomography (CT) indicated improvements in the hydroxychloroquine and chloroquine pharmacologic categories. This research provides evidence that hydrochlorothiazide may be used to treat mild COVID-19, and it complements more excellent investigations.